Hospital-acquired infections caused by enterococci: a systematic review and meta-analysis, WHO European Region, 1 January 2010 to 4 February 2020.

Euro Surveill

Unit 37: Nosocomial Infections, Surveillance of Antimicrobial Resistance and Consumption, Robert Koch Institute, Berlin, Germany.

Published: November 2021

BackgroundHospital-acquired infections (HAI) caused by spp., especially vancomycin-resistant (VRE), are of rising concern.AimWe summarised data on incidence, mortality and proportion of HAI caused by enterococci in the World Health Organization European Region.MethodsWe searched Medline and Embase for articles published between 1 January 2010 and 4 February 2020. Random-effects meta-analyses were performed to obtain pooled estimates.ResultsWe included 75 studies. spp. and VRE accounted for 10.9% (95% confidence interval (CI): 8.7-13.4; range: 6.1-17.5) and 1.1% (95% CI: 0.21-2.7; range: 0.39-2.0) of all pathogens isolated from patients with HAI. Hospital wide, the pooled incidence of HAI caused by spp. ranged between 0.7 and 24.8 cases per 1,000 patients (pooled estimate: 6.9; 95% CI: 0.76-19.0). In intensive care units (ICU), pooled incidence of HAI caused by spp. and VRE was 9.6 (95% CI: 6.3-13.5; range: 0.39-36.0) and 2.6 (95% CI: 0.53-5.8; range: 0-9.7). Hospital wide, the pooled vancomycin resistance proportion among spp. HAI isolates was 7.3% (95% CI: 1.5-16.3; range: 2.6-11.5). In ICU, this proportion was 11.5% (95% CI: 4.7-20.1; range: 0-40.0). Among patients with hospital-acquired bloodstream infections with spp., pooled all-cause mortality was 21.9% (95% CI: 15.7-28.9; range: 14.3-32.3); whereas all-cause mortality attributable to VRE was 33.5% (95% CI: 13.0-57.3; range: 14.3-41.3).ConclusionsInfections caused by spp. are frequently identified among hospital patients and associated with high mortality.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646982PMC
http://dx.doi.org/10.2807/1560-7917.ES.2021.26.45.2001628DOI Listing

Publication Analysis

Top Keywords

hai caused
16
caused spp
16
95%
9
caused enterococci
8
january 2010
8
2010 february
8
february 2020
8
spp vre
8
range
8
hospital wide
8

Similar Publications

[Meta-analysis of the efficacy of the Fuzheng Huayu formula in the treatment of hepatitis B-associated liver fibrosis or cirrhosis].

Zhonghua Gan Zang Bing Za Zhi

December 2024

Center of Hepatology and Department of Infectious Disease, Jinling Hospital (General Hospital of Eastern Theater Command) Affiliated to School of Medicine, Nanjing University, Nanjing210002, China.

To systematically evaluate the efficacy of Fuzheng Huayu (FZHY) tablets/capsules on hepatitis B-associated liver fibrosis or cirrhosis based on randomized controlled trials (RCTs) in order to provide more accurate evidence-based medicine for clinical rational drug use. Randomized controlled clinical trial research reports related to the treatment of hepatitis B-associated liver fibrosis or cirrhosis with FZHY published in SCI and statistical source core journals were retrieved from databases such as PubMed, Cochrane Library, and China National Knowledge Infrastructure (CNKI). RevMan 5.

View Article and Find Full Text PDF

[Research progress on clinical evaluation index of brain function after cardiopulmonary resuscitation].

Zhonghua Wei Zhong Bing Ji Jiu Yi Xue

December 2024

Department of Anesthesiology, People's Hospital of Ningxia Hui Autonomous Region (the Third Medical College of Ningxia Medical University), Yinchuan 750001, Ningxia Hui Autonomous Region, China. Corresponding author: Hai Kerong, Email:

The ultimate goal of cardiac arrest-cardiopulmonary resuscitation (CA-CPR) is to reduce brain damage and promote neurological recovery. Although the return of spontaneous circulation (ROSC) has improved, the proportion of patients who survive to discharge is very low, so how to evaluate the recovery of brain function after resuscitation is particularly important in clinical work. From a clinical perspective, although early prognostic indicators are not perfect, identifying high-risk features may help clinicians determine the severity of brain injury caused by a patient's potential course of disease.

View Article and Find Full Text PDF

Balancing fairness and efficiency in dynamic vaccine allocation during major infectious disease outbreaks.

Sci Rep

January 2025

School of Economics and Management, Beijing Jiaotong University, No.3 Shangyuan Cun, Haidian District, Beijing, 100044, People's Republic of China.

The outbreak of novel infectious diseases presents major public health challenges, highlighting the urgency of accelerating vaccination efforts to reduce morbidity and mortality. Vaccine allocation has become a crucial societal concern. This paper introduces a dynamic vaccine allocation model that considers demand uncertainty and vaccination willingness, focusing on the trade-off between fairness and efficiency.

View Article and Find Full Text PDF

The COVID-19 infection caused by SARS-CoV-2 in late 2019 posed unprecedented global health challenges of massive proportions. The persistent effects of COVID-19 have become a subject of significant concern amongst the medical and scientific community. This article aims to explore the probability of a link between the COVID-19 infection and the risk of lung cancer development.

View Article and Find Full Text PDF

Background: Healthcare-associated infections (HAI) caused by multidrug-resistant organisms have emerged as a significant global issue, posing substantial challenges to healthcare systems. Low- and intermediate-level disinfectants are extensively utilized for cleaning and disinfecting surfaces in hospitals to mitigate environmental transmission of HAI. Therefore, the need for more effective and environmentally safe disinfectants is increasing.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!